Equillium (NASDAQ:EQ) Insider Penny Tom Sells 65,000 Shares of Stock

Equillium, Inc. (NASDAQ:EQ) insider Penny Tom sold 65,000 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $2.95, for a total transaction of $191,750.00. Following the transaction, the insider directly owned 65,000 shares in the company, valued at $191,750. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Equillium Price Performance

NASDAQ EQ traded up $0.06 during trading on Friday, reaching $2.90. 853,917 shares of the company’s stock traded hands, compared to its average volume of 480,896. The firm has a market cap of $183.37 million, a price-to-earnings ratio of -9.06 and a beta of 1.67. The company’s 50 day simple moving average is $2.09 and its two-hundred day simple moving average is $1.63. Equillium, Inc. has a 12-month low of $0.27 and a 12-month high of $3.10.

Equillium (NASDAQ:EQ) last posted its earnings results on Wednesday, May 13th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Research analysts expect that Equillium, Inc. will post -0.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Raymond James Financial reissued a “strong-buy” rating and set a $7.00 target price on shares of Equillium in a research report on Thursday. Stifel Nicolaus set a $5.00 target price on shares of Equillium in a research report on Thursday. Oppenheimer initiated coverage on shares of Equillium in a report on Thursday, April 23rd. They issued an “outperform” rating and a $7.00 price target on the stock. Leerink Partners upgraded shares of Equillium from a “market perform” rating to an “outperform” rating and raised their price target for the company from $1.00 to $6.00 in a report on Thursday. Finally, Cantor Fitzgerald initiated coverage on shares of Equillium in a report on Tuesday, April 7th. They issued an “overweight” rating and a $10.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $7.57.

Institutional Trading of Equillium

Institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC acquired a new stake in Equillium in the 4th quarter worth approximately $9,057,000. ADAR1 Capital Management LLC purchased a new stake in Equillium during the 3rd quarter worth approximately $7,951,000. Woodline Partners LP purchased a new stake in Equillium during the 3rd quarter worth approximately $5,018,000. Aberdeen Group plc grew its position in Equillium by 523.6% during the 4th quarter. Aberdeen Group plc now owns 2,366,688 shares of the company’s stock worth $3,668,000 after purchasing an additional 1,987,162 shares during the last quarter. Finally, Eversept Partners LP purchased a new stake in Equillium during the 1st quarter worth approximately $2,998,000. 27.05% of the stock is currently owned by institutional investors.

Key Headlines Impacting Equillium

Here are the key news stories impacting Equillium this week:

• Positive Sentiment: Leerink Partners upgraded Equillium from market perform to outperform and lifted its price target to $6.00, suggesting meaningful upside from current levels. Leerink Upgrades Equillium (EQ) to Outperform
• Positive Sentiment: Roth Mkm reiterated a buy rating and set a $12.00 target, reinforcing a bullish view on Equillium’s pipeline and valuation. Equillium Receives Buy Rating from Roth Mkm
• Positive Sentiment: Equillium announced it will participate in the 2026 Jefferies Global Healthcare Conference, which could provide a catalyst if management shares favorable clinical or strategic updates. Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
• Positive Sentiment: Shareholders approved a reverse split and capital changes at the annual meeting, a step that can help maintain Nasdaq compliance and potentially improve the company’s capital structure. Equillium Shareholders Approve Reverse Split and Capital Changes
• Neutral Sentiment: Short interest was reported at 0 shares, indicating no meaningful bearish positioning in the latest update, though the figure appears unusual and may not be a reliable market signal. Short interest update
• Negative Sentiment: COO Christine Zedelmayer sold a combined 95,833 shares over two transactions, and insider Penny Tom sold 65,000 shares; although both were made under pre-arranged 10b5-1 plans, insider selling can still pressure sentiment. SEC Form 4 insider sales filing

Equillium Company Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.